Exploratory analysis of gene aberrations and chemotherapy response: findings from a real-world database in Japan.

ABSTRACT:

Background

Chemotherapy selection traditionally relies on tumor tissue of origin. However, since genetic alterations drive tumor behavior, it remains unclear if mutations can better predict response. We hypothesized that genetic aberrations might influence chemotherapy outcomes more than tissue origin.

Methods

We retrospectively analyzed 15,474 Japanese patients with solid tumors who underwent comprehensive genomic profiling (CGP) and received cytotoxic chemotherapy. Genetic alterations and tumor origin were evaluated for objective response rate (ORR) and time to next treatment (TNT). Gene mutations were assessed across five chemotherapy classes: platinum-based, alkylating agents, antimetabolites, microtubule inhibitors, and topoisomerase inhibitors.

Results

Genomic a

SUBMITTER: Ishibashi N 

PROVIDER: S-EPMC12905273 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature